Abstract Bladder cancer (BC) remains one of the most common cancer worldwide. Radical cystectomy (RC) and pelvic lymph node dissection (PLND) with urinary diversion (UD) is still considered the gold standard treatment for non-metastatic muscle invasive bladder cancer (MIBC) and for recurrent non-muscle invasive disease. The open approach remains the reference option of treatment for RC, even if robotic surgery is rapidly increasing. Nowadays, several studies have reported perioperative, functional and oncological outcomes of robot-assisted radical cystectomy (RARC), but data are still immature to compare both procedures. All the current randomized controlled trials (RCTs), did not prove any significant difference between open RC and RARC, underlining no superiority between both procedures. Therefore, RARC is still considered an investigational procedure. On the other hand, modern robotic surgical practice has been evolved by the introduction of innovative technologies. The technological progress is improving, in particular in robotic surgery, offering several future perspectives, such as the ICG technique. The aim of the review is to describe the state of art, and to outline future perspectives of RARC, in order to establish the role of robotic surgery in the complex field of radical cystectomy.

Key words bladder cancer, radical cystectomy, robot-assisted radical cystectomy, urinary diversion, robotic surgery
Introduction

Bladder cancer (BC) remains one of the most common cancer worldwide. BC is the 7th most commonly diagnosed cancer in males, and the 11th when both genders are considered. In the European Union, the age-standardised incidence rate is 19.1 for men, and 4.0 for women [1]. In Italy, in 2017 it has reported 27,000 new diagnosis of BC (21,700 for men and 5,300 for women), in particular at diagnosis 70% of patients has a non-invasive BC while 30% of patients has a muscle-invasive disease [2].

Radical cystectomy (RC) and pelvic lymph node dissection (PLND) with urinary diversion (UD) still remains the gold standard treatment for non-metastatic muscle invasive bladder cancer (MIBC) and for recurrent non-muscle invasive disease [1]. Actually, it is growing the literature about multimodality treatment (MMT) or trimodality treatment combines TURB, chemotherapy and radiation. The evidences supporting a bladder-sparing approach to treat BC are few, and the impact of MMT, as compared to RC, on long-term overall survival (OS) remains undefined. As a result, MMT could be offered as an alternative in highly selected patient population, especially for whom cystectomy is not an option [1, 3, 4]. Therefore, many patients continue to be offered radical surgery as the standard-of-care treatment.

Open Radical Cystectomy vs Robot-assisted Radical Cystectomy: state of art

The open approach is still considered the reference option of treatment for RC, even if the widespread use of robotic surgery is progressively changing this statement. However, data are immature to compare both approaches, therefore robot-assisted laparoscopic radical cystectomy (RARC) is still considered an investigational procedure. Several studies have reported that robotic approach reduces blood loss and transfusions, and it has a shorter length of hospital stay compared to open radical cystectomy (ORC) [5,6]. Despite these evidences, all the current randomized controlled trials (RCTs), including intermediate and long-term oncologic and functional outcomes, did not prove any significant difference (Table 1 - 2, Figure 1 - 2) [7–12].

Simone et al. [5] reported a propensity scored (PS) match analysis, to compare perioperative and mid-term oncologic outcomes of RARC with totally intracorporeal neobladder and open cohort, from a single center series. The open cohort analysis, to compare perioperative and mid-term oncologic outcomes of RARC (as compared to RC, on long-term overall survival (OS) remains undefined. As a result, MMT could be offered as an alternative in highly selected patient population, especially for whom cystectomy is not an option [1, 3, 4]. Therefore, many patients continue to be offered radical surgery as the standard-of-care treatment.

Table 1. Perioperative outcomes of RARC.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Patients (n)</th>
<th>EBL (ml)</th>
<th>LS (days)</th>
<th>LG complications (%)</th>
<th>HG complications (%)</th>
<th>Intracorporeal UD (%)</th>
<th>Extracorporeal UD (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simone et al [5, 23]</td>
<td>2018</td>
<td>64</td>
<td>210</td>
<td>8</td>
<td>36</td>
<td>6</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>Khan et al [7]</td>
<td>2016</td>
<td>20</td>
<td>585</td>
<td>11.9</td>
<td>25</td>
<td>30</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Bochner et al [8]</td>
<td>2015</td>
<td>60</td>
<td>516</td>
<td>8</td>
<td>62</td>
<td>22</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Nix et al [10]</td>
<td>2009</td>
<td>21</td>
<td>258</td>
<td>5.1</td>
<td>29</td>
<td>6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Parekh et al [11]</td>
<td>2018</td>
<td>150</td>
<td>300</td>
<td>6</td>
<td>78</td>
<td>22</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Gandaglia et al [12]</td>
<td>2016</td>
<td>138</td>
<td>300</td>
<td>13</td>
<td>44</td>
<td>16</td>
<td>31</td>
<td>69</td>
</tr>
</tbody>
</table>

EBL: estimated blood loss; LS: length of stay; LG: low grade; HG: high grade; UD: urinary diversion.
Figure 1. A: Isolation of ureter and umbilical artery; B: Incision of Douglas above the seminal vesicles; C: Opening of endopelvic fascia; D: Identification of vascular pedicle; E: Developing the space of Retzius; F: Section of dorsal vein complex (DVC); G: Clip ligation and section of ureter; H: Urethra incision; I: section of posterior urethra; J: section of Rectourethral muscle
mean LN-c of 33.4 (± 12.3) and 30.7 (± 14.1) for robotic and open approach (P = 0.16), respectively.

Intracorporeal vs extracorporeal Robot-assisted Urinary Diversion

The creation of urinary diversion is considered the most challenging step after RARC [16]. Therefore, despite it is growing the use of RARC, the majority of the centres still feel more confident performing an extracorporeal (ECUD) instead of a totally intracorporeal (ICUD) urinary diversion. Actually, underutilization of the intracorporeal approach might jeopardize an accurate interpretation of the results of current studies [6]. Indeed, data from the International Robotic Cystectomy Consortium (IRCC) showed that ICUD is performed in 72% of cases, whereas the ileal orthotopic neobladder only in 27%, of which 82% utilize the extracorporeal approach [17]. Initially confined to high-volume centers, ICUD after RARC is also becoming popular since it provides quicker recovery of bowel function, shorter hospital stay and earlier return to daily life activities. Different types of ICUD

Table 2 Oncologic outcomes of RARC.

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Patients (n)</th>
<th>PSM (%)</th>
<th>LNc (mean)</th>
<th>DFS</th>
<th>CSS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simone et al [5, 23]</td>
<td>2018</td>
<td>64</td>
<td>0</td>
<td>33.4</td>
<td>87.8¹</td>
<td>89.6¹</td>
<td>85.2¹</td>
</tr>
<tr>
<td>Khan et al [7]</td>
<td>2016</td>
<td>20</td>
<td>15</td>
<td>16.3</td>
<td>73.7²</td>
<td>100²</td>
<td>95²</td>
</tr>
<tr>
<td>Bochner et al [8]</td>
<td>2015</td>
<td>60</td>
<td>3.6</td>
<td>31.9</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Nix et al [10]</td>
<td>2009</td>
<td>21</td>
<td>0</td>
<td>19</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Gandaglia et al [12]</td>
<td>2016</td>
<td>138</td>
<td>8.7</td>
<td>12</td>
<td>54.2³</td>
<td>73.5³</td>
<td>59.2³</td>
</tr>
</tbody>
</table>

PSM: positive surgical margins; LNc: lymph node count; DFS: disease free survival; CSS: cancer specific survival; OS: overall survival. ¹2-yr follow-up; ²1-yr follow-up; ³5-yr follow-up; NA: not available
have been reported such as: ileal conduit, orthotopic neobladder and continent cutaneous diversion. EAU guidelines underline that although an intracorporeal neobladder is a more complex procedure, the choice of urinary diversion must not depend on the surgical approach [1].

Firstly, Intracorporeal ileal conduit is the most commonly performed, because of its simplicity, speed and safety execution with a low complication rate [18]. Secondly, orthotopic neobladder is still considered the most challenging ICUD, and several revisions of standard open reservoir configurations have been proposed to shorten the operative time of the robotic technique [19-22]. Simone G. et al. [23] reported the technique for the completely intracorporeal Padua ileal bladder (PIB) configuration. They reported a 44.4% of perioperative complication rate, of which 17.8% of patients experienced a severe complication (Clavien grade ≥ 3). Moreover, a significant decrease (P < 0.003) of mean operative time was observed in the last tertile, compared to the first one, and a trend towards significance was observed also for overall complications (P = 0.065), high-grade complications (P = 0.068) and duration of hospital stay (P = 0.06). This underline the need of an high-volume center and a long learning curve to standardize the procedure, gaining the advantages of a minimally invasive approach. Regarding functional outcomes, 2-year day-time and night-time continence rates were 73.3% and 55.5%, respectively. Finally, when patients are not candidates for orthotopic neobladder, a continent cutaneous diversion (CCD) should be a viable option. Desai M. et al. [24] showed their experience with intracorporeal Indiana pouch. They reported a median total operative time of 6 hours, including 3.5 hours for pouch reconstruction. It has reported a 40% Clavien grade 1-2 complications rate, and a 30% Clavien 3-5 complications rate. At a median follow-up of 13.7 months, all patients were completely continent. Clearly, we need more data.

Figure 3. Extended Pelvic Lymph Node Dissection (e-PLND). A: External iliac nodes; B: Obturator fossa; C: Presacral nodes; D: Final template; E: e-PLND template diagram: a) Common iliac nodes b) internal iliac nodes c) presacral nodes d) external iliac nodes.
with longer follow-up to assess the role of CCD as a valid option for UD, in particular to better evaluate long-term complications such as stone formation rate, around 10.8% in some large series, and stomal stenosis that is reported in 23.5% of patients [25].

New technologies in robotic surgery: state of art and future perspectives

Nowadays, RC is still considered a challenging procedure with high rate of complications. Hautmann R.E. et al. [26] in a large single-centre series described an early 90-day complication rate of 58%, at the same time, Novara G, et al. [27] reported a 3-month mortality rate of 3% and a complication rate of 49%, of which 13% were grade 3 to 5. Moreover, early morbidity of RC, in patients with recurrent non-muscle invasive disease, is comparable in patients with MIBC [28], therefore surgical procedure is the key point to reduce overall complication rate.

Recently, we underline the importance to follow the technological progress in robotic surgery field, in order to outclass the ancient concept of “replicating the open principles” [29]. From the beginning of the robotic era up to day several studies reported comparable oncologic and functional outcomes between RARC and ORC, emphasizing no superiority between the two procedures. We are strongly convinced that this is the first step to establish the role of robotic surgery in the management of BC, and now the technological revolution will guide robotic surgery to affirm its definitive role. It is growing the interest about the role of near-infrared fluorescence technology that is able to augment anatomical structures identification. Manny TB et al. [30] described the feasibility of fluorescence-enhanced robotic radical cystectomy, using real-time cystoscope injection of indocyanine green (ICG), for tumor marking and identification of sentinel lymphatic drainage. It has reported a 90% of rate to identify sentinel nodal drainage, and in terms of ability to identify nodal metastasis, they found ICG lymphangiography to be highly sensitive. The different applications of ICG to evaluate bowel vascularity were first explored during RARC [19, 31, 32]. During intracorporeal robotic urinary diversion is more difficult to identify mesenteric arcades, therefore the ICG technique could be an easy way to maximize vascular preservation, avoiding gastrointestinal complications, that are considered the most common after RARC [33]. Moreover, the role of ICG technique to easily recognize tissue vascular perfusion was used to prevent ischemic ureteral complications, such as strictures. Ahmad et al. [34] reported a significant reduction in the per-patient rate of uretero-entrant anastomotic stricture from 10, 6% to 0% (p = 0.020).

Conclusion

In conclusion, even if RCTs failed to reveal a significant superiority of RARC compared to ORC [35], at the same time, it has to be considered that its non-inferiority is the start point to improve this investigational procedure. The current technological development, related to robotic surgery, is rapidly increasing, offering several future perspectives, that will definitely establish the role of robotic surgery in the complex field of radical cystectomy.

Funding

None.

Ethics approval and consent to participate

This study did not require prior ethics approval or consent from human participants.


